IP Library Granted Patent US 11,826,154
Granted Patent B2
US 11,826,154 · App. 16/680,934 · Granted Nov 28, 2023

Method and system for identification of source of chronic pain and treatment

Inventors: Eric A. Schepis (Alpharetta, GA); Phillip A. Schorr (Cumming, GA); Joshua D. White (Atlanta, GA)
Assignee: Avent, Inc.
A61B5/369A61B5/0538A61B5/377A61B5/4047A61B5/4824A61B5/4848A61B5/4893A61B18/148A61N1/36021A61B5/01A61B5/318A61B5/389A61B2018/00011A61B2018/0091A61B2018/00434A61B2018/00577A61B2018/00642A61B2018/00702A61B2018/00744A61B2018/00791
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,826,154
App. No.
16/680,934
Granted
Nov 28, 2023
Kind
B2
Abstract

A method for identifying and treating a neural pathway associated with chronic pain via nerve stimulation and brain wave monitoring of a mammalian brain is described. The method includes positioning a probe to stimulate a target nerve, wherein the target nerve is suspected of being a source of chronic pain; delivering a first nerve stimulation from the probe to the target nerve, wherein the first nerve stimulation is sufficient to elicit a chronic pain response in the brain; and monitoring for evoked potential activity in the brain as a result of the first nerve stimulation. The method can also include delivering second and third nerve stimulations to confirm the correct identification of the neural pathway and to treat the chronic pain, respectively. A system and apparatus for performing a procedure to identify and treat a nerve that is the source of chronic pain are also described.

Claims (39)

1. An apparatus for treating chronic pain, the apparatus comprising:

at least one probe for delivering multiple nerve stimulations to a target nerve, wherein the target nerve is suspected of being a source of chronic pain;

a monitor configured to display multiple views; and

a controller communicably coupled to the monitor and electrically coupled to the at least one probe, the controller configured to:

deliver, via the at least one probe, to the target nerve, a first electrical nerve stimulation to cause the target nerve to elicit a chronic pain response in one or more predetermined regions of the brain associated with chronic pain;

identify, by the controller, the target nerve as the source of chronic pain by monitoring first brain wave activity as a result of the first electrical nerve stimulation to determine whether the chronic pain response is elicited;

deliver, via the at least one probe, to the target nerve, a second electrical nerve stimulation to reversibly or temporarily block transmission of signals via the target nerve upon identifying the target nerve as the source of chronic pain;

verify, by the controller, that the target nerve is the source of chronic pain by monitoring second brain wave activity as a result of the second electrical nerve stimulation and confirming that the transmission of signals via the target nerve has been blocked; and

deliver, via the at least one probe, to the target nerve, a third nerve stimulation to impair or alter the target nerve upon verifying that the target nerve is the source of chronic pain.

2. The apparatus of claim 1 , wherein the at least one probe is an RF probe.

3. The apparatus of claim 1 , wherein the at least one probe comprises two or more probes.

4. The apparatus of claim 3 , comprising multiple channels each corresponding to one of the more than one RF probes, wherein each channel is configured to treat a different source of chronic pain.

5. A method for identifying and treating a neural pathway associated with chronic pain via nerve stimulation and brain wave monitoring of a mammalian brain, the method comprising:

positioning a probe to stimulate a target nerve, wherein the target nerve is suspected of being a source of chronic pain;

delivering, by a controller, a first nerve stimulation from the probe to the target nerve at a first frequency and a first amplitude that elicit a chronic pain response in the brain;

monitoring, by the controller, evoked potential activity in one or more predetermined regions of the brain as a result of the first nerve stimulation to detect whether the first nerve stimulation elicits the chronic pain response in the brain, wherein the one or more predetermined regions of the brain are regions associated with chronic pain;

delivering, by the controller, a second nerve stimulation from the probe to the target nerve at a second frequency and a second amplitude that reversibly blocks transmission of signals via the target nerve in order to verify that the target nerve is the source of chronic pain;

monitoring, by the controller, the evoked potential activity in the one or more predetermined regions of the brain as the second nerve stimulation is delivered to verify that the target nerve is part of the neural pathway associated with the chronic pain by confirming that the transmission of signals in the target nerve have been blocked if minimal or no evoked potential activity is detected; and

treating the chronic pain by delivering, by the controller, a third nerve stimulation from the probe to the target nerve at a third frequency and a third amplitude that impairs the neural pathway associated with the chronic pain after the target nerve has been verified based on the second nerve stimulation.

6. The method of claim 5 , further comprising monitoring, by the controller, for evoked potential activity in one or more predetermined regions of the brain, wherein the presence of evoked potential activity in the one or more predetermined regions of the brain indicates the target nerve is part of the neural pathway associated with chronic pain.

7. The method of claim 5 , wherein monitoring for evoked potential activity comprises measuring, by the controller, evoked potential amplitude, wherein an increase in evoked potential amplitude indicates the probe is positioned closer to the source of the chronic pain and a decrease in evoked potential amplitude indicates the probe is positioned farther away from the source of the chronic pain.

8. The method of claim 5 , wherein monitoring for evoked potential activity comprises measuring, by the controller, evoked potential latency, wherein a decrease in evoked potential latency indicates the probe is positioned closer to the source of the chronic pain and an increase in evoked potential latency indicates the probe is positioned farther away from the source of the chronic pain.

9. The method of claim 5 , wherein monitoring for evoked potential activity comprises measuring, by the controller, evoked potential frequency, wherein an increase in evoked potential frequency indicates the probe is positioned closer to the source of the chronic pain and a decrease in evoked potential frequency indicates the probe is positioned farther away from the source of the chronic pain.

10. The method of claim 5 , further comprising monitoring, by the controller, for evoked potential activity in one or more predetermined regions of the brain, wherein the presence of evoked potential activity with a predetermined amplitude, a predetermined latency, a predetermined frequency, a predetermined shape, or a combination thereof in the one or more predetermined regions of the brain indicates the target nerve is part of the neural pathway associated with chronic pain.

11. The method of claim 5 , wherein monitoring for evoked potential activity comprises measuring, by the controller, evoked potential amplitude, evoked potential latency, evoked potential frequency, evoked potential shape, or a combination thereof, wherein observation of an evoked potential with an amplitude, a latency, a frequency, a shape, or a combination thereof at a predetermined stimulation indicates the target nerve is in close enough proximity to the part of the neural pathway associated with chronic pain for treatment of the chronic pain.

12. The method of claim 11 , wherein the target nerve is determined not to be a part of the neural pathway associated with chronic pain if the monitored brain wave activity indicates that the target nerve is able to transmit signals after the second stimulation is delivered.

13. The method of claim 5 , further comprising:

verifying, by the controller, that impairment of the neural pathway is complete by repeating the first nerve stimulation, the second nerve stimulation, or both to confirm impairment of the target nerve, wherein impairment is complete if brain wave activity consistent with effective impairment of the neural pathway is observed.

14. The method of claim 5 , further comprising:

delivering, by the controller, an additional nerve stimulation to an additional nerve via the probe, wherein the additional nerve is not suspected of being a source of chronic pain, wherein the additional nerve stimulation elicits a response in the brain; and

monitoring, by the controller, baseline brain activity, evoked potential activity in the brain as a result of the additional nerve stimulation, or both, via electroencephalography electrodes coupled to the controller.

15. The method of claim 14 , further comprising:

comparing, by the controller, the elicited response from the additional nerve stimulation to the elicited response from the first nerve stimulation to verify that the target nerve is correctly identified as part of the neural pathway associated with chronic pain, wherein a difference in the elicited response from the additional nerve stimulation compared to the elicited response from the first nerve stimulation indicates that the target nerve is part of the neural pathway associated with chronic pain.

16. The method of claim 5 , wherein monitoring for evoked potential activity is performed via electroencephalography.

17. The method of claim 5 , wherein the probe is a percutaneous probe.

18. The method of claim 5 , wherein the first frequency is 100 Hertz or less, and wherein the first amplitude ranges from 0.01 milliamps to 50 milliamps.

19. The method of claim 18 , wherein the first nerve stimulation is delivered as a square wave, wherein each pulse of the square wave has a duration ranging from 0.01 milliseconds to 10 milliseconds.

20. The method of claim 5 , wherein the second frequency ranges from 1,000 Hertz to 100,000 Hertz, and wherein the second amplitude ranges from 0.01 milliamps to 50 milliamps.

21. The method of claim 5 , wherein the third frequency ranges from 100,000 Hertz to 1.5 Megahertz, and wherein the third amplitude is up to 1.4 Amps.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 28, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AVENT, INC.; AVANOS MEDICAL SALES, LLC
Reel/Frame 076077/0108 →
SECURITY INTEREST Recorded Jul 27, 2026
From: AVENT, INC.
To: GOLUB CAPITAL MARKETS LLC, AS COLLATERAL AGENT
Reel/Frame 076066/0888 →
SECURITY INTEREST Recorded Jun 24, 2022
From: AVENT, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060441/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2019
From: SCHEPIS, ERIC A.; SCHORR, PHILLIP A.; WHITE, JOSHUA D.
To: AVENT, INC.
Reel/Frame 050981/0815 →
Continuity (3)
Division 15501445
Provisional Application 62041798 · Aug 26, 2014
Related Publication 20200077916A1 · Mar 12, 2020